NEW YORK, February 26, 2025 — A particularly tenacious fungal infection, Candida auris, is gaining ground globally and becoming increasingly resistant to treatment, according to a new analysis of the latest research.
But it’s not a hopeless situation. Scientists are actively developing new strategies to combat this invasive germ, detailed in a review published in the journal Microbiology and Molecular Biology Reviews.
What is Candida auris and why should you care? This emerging fungal pathogen poses a serious threat, particularly to those with weakened immune systems, due to its ability to resist common antifungal drugs and its knack for spreading in healthcare settings.
The review, authored by Neeraj Chauhan, Ph.D., of the Hackensack Meridian Center for Discovery and Innovation, alongside Anuradha Chowdhary, Ph.D., of the University of Delhi, and Michail Lionakis, M.D., Sc.D., of the National Institutes of Health, synthesizes current understanding of this evolving threat.
Approximately 6.5 million people worldwide are affected by invasive fungal infections each year, many with devastating outcomes. C. auris, first identified in 2009 in Japan from an ear infection sample, has rapidly spread since then, raising concerns among public health officials.
Some theories suggest that climate change may be playing a role in the emergence and spread of C. auris, though the exact mechanisms are still under investigation. What is clear is that this fungus has some unique adaptations that make it particularly challenging to treat.
The cell wall of C. auris differs significantly from other fungal species, boasting a sugar-rich structure that contributes to its drug resistance and ability to interact with its host. It’s also a master of disguise, capable of shifting between yeast and filament forms, forming multicellular clumps, and altering its genetic expression to survive in changing environments.
Perhaps most alarmingly, C. auris excels at colonizing human skin, with its cell wall proteins acting like an adhesive, sticking to both mammalian cells and inanimate surfaces. This makes it incredibly difficult to eradicate from healthcare environments.
While the human body does mount a defense against C. auris, the fungus has evolved ways to evade the immune response. However, researchers are optimistic about the potential for new vaccines and treatments.
Currently, four classes of antifungal drugs are available, many developed decades ago. Fortunately, three new drugs are in clinical trials or recently approved, offering a glimmer of hope.
Accurate diagnosis remains a significant hurdle. Conventional lab tests often misidentify C. auris as other, less dangerous yeasts, delaying appropriate treatment. Increased awareness and improved surveillance are crucial, particularly in countries with limited resources.
“Taken together, these data underscore the need to develop novel antifungal agents with broad-spectrum activity against human fungal pathogens, to improve diagnostic tests, and to develop immune- and vaccine- based adjunct modalities for the treatment of high-risk patients,” the authors write. “In addition, future efforts should focus on raising awareness about fungal disease through developing better surveillance mechanisms, especially in resource-poor countries.”
They conclude that these advancements are essential to improving outcomes for patients battling opportunistic fungal infections.
What can be done to prevent the spread of Candida auris? Strict infection control measures in healthcare facilities, rapid and accurate diagnostics, and continued research into new treatments are all vital steps.
Worth a look
